Kisspeptin-54 attenuates oxidative stress and neuronal apoptosis in early brain injury after subarachnoid hemorrhage in rats via GPR54/ARRB2/AKT/GSK3β signaling pathway.
Huang. Yi Y; Guo. Yong Y; Huang. Lei L; Fang. Yuanjian Y; Li. Dujuan D; Liu. Rui R; Lu. Qin Q; Ren. Reng R; Tang. Lihui L; Lian. Lifei L; Hu. Yongmei Y; Tang. Jiping J; Chen. Gao G; Zhang. John H JH
Key Findings
- Intranasal kisspeptin-54 (1.0 nmol/kg) lowered oxidative stress and neuronal apoptosis after subarachnoid hemorrhage in rats.
- Blocking the GPR54 receptor or removing the adaptor protein ARRB2 eliminated the neuroprotective benefits of kisspeptin-54.
- Animals treated with kisspeptin-54 showed improved neurological scores and better cognitive performance up to 28 days post‑injury.
Practical Outcomes
- For biohackers, this study suggests kisspeptin‑54 can act as a brain‑protective antioxidant in a severe injury model, but it’s only been tested in rats with a specific type of brain bleed. No human dosing, safety, or efficacy data exist yet, so it isn’t ready for personal use or protocol development.
Summary
In rats that had a brain bleed, giving a form of the peptide kisspeptin-54 through the nose reduced brain damage, oxidative stress, and cell death, and helped the animals recover better over weeks. The protective effect depended on a specific receptor (GPR54) and downstream signaling proteins.
Abstract
Oxidative stress-induced neuron apoptosis plays a crucial role in the early brain injury (EBI) after subarachnoid hemorrhage (SAH). Kisspeptin has been reported as antioxidant to reduce oxidative stress-induced neuronal cell death through G protein-coupled receptor 54 (GPR54). The goal of this study was to determine the neuroprotection of the Kisspeptin/GRP54 signaling pathway against EBI after SAH. Two hundred and ninety-two Sprague Dawley male rats were used and SAH was induced by the endovascular perforation. Exogenous Kisspeptin 54 (KP54) was delivered intranasally. Small interfering ribonucleic acid (siRNA) for endogenous KISS1, a selective GPR54 antagonist kisspeptin 234, or β-arrestin 2 siRNA for ARRB2 (a functional adaptor of GPR54) were administered intracerebroventricularly. Post-SAH evaluations included neurobehavioral tests, SAH grade, Western blot, immunofluorescence, Fluoro-Jade C, TUNEL, and Nissl staining. The results showed that endogenous KISS1 knockdown aggravated but exogenous KP54 (1.0 nmol/kg) treatment attenuated neurological deficits, brain oxidative stress, and neuronal apoptosis at 24 h after SAH. The benefits of KP54 persisted to 28 days after SAH, which significantly improved cognitive function in SAH rats. The GPR54 blockade or the ARRB2 knockout offset the neuroprotective effects of KP54 in SAH rats. In conclusion, our results suggested that administration of KP54 attenuated oxidative stress, neuronal apoptosis and neurobehavioral impairments through GPR54/ARRB2/AKT/GSK3β signaling pathway after SAH in rat. Thus, KP54 may provide an effective treatment strategy for SAH patients.
Study Information
pubmed
2021
2021-05-11T00:00:00.000Z
10.1016/j.freeradbiomed.2021.05.012
31
51